Evidence map›Paper›PMID 32591493›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2021

FAPI-74 PET/CT Using Either

Frederik L Giesel, Sebastian Adeberg, Mustafa Syed, Thomas Lindner, Luis David Jiménez-Franco, Eleni Mavriopoulou, Fabian Staudinger, Eric Tonndorf-Martini, Sebastian Regnery, Stefan Rieken and 8 more

5 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 154 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed, 5 pooled it
13.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05687747 phase1recruitingnot on this mapstarted 2023, after this paper: background citation

Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma

TypeinterventionalSponsorNational University Hospital, SingaporeRan2023 to 2026Enrolled100ConditionsHepatocellular CarcinomaArmsRadiolabelled tracer, 68Gallium-FAPI-46 PET/MRI
NCT06191120 narecruitingnot on this mapstarted 2024, after this paper: background citation

FAPI Molecular Imaging for Diagnosis of the CMS4 Unfavorable Colorectal Cancer Subtype

TypeinterventionalSponsorUMC UtrechtRan2024 to 2031Enrolled45ConditionsMetastatic Colorectal Cancer, Metastatic Cancer to LiverArms[18F]-ALF-FAPI-74 PET/CT scan
NCT06252610 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

PET/MRI Evaluation in Patients With Primary Sclerosing Cholangitis Using Intercellular Matrix Radiopharmaceuticals

TypeobservationalSponsorMassachusetts General HospitalRan2026 to 2029Enrolled10ConditionsPSCArmsRadiotracer Injection, Contrast Media, Magnetic Resonance, Imaging
NCT06377553 enrolling by invitationnot on this mapstarted 2025, after this paper: background citation

PET/MRI Evaluation of Endometriosis Using Intercellular Matrix Radiopharmaceuticals

TypeobservationalSponsorMassachusetts General HospitalRan2025 to 2029Enrolled60ConditionsEndometriosis, EndometriomaArmsRadiotracer Injection, Imaging, Rectal Ultrasound Gel Injection
NCT06568783 phase2not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Evaluation of Patients With Refractory Dermatomyositis Using [18F]- Fibroblast Activation Protein Inhibitor-74 (FAPI-74) PET/MRI Imaging

TypeinterventionalSponsorFarshad MoradiRan2024 to 2028Enrolled21ConditionsRefractory DermatomyostitisArms[18F]-FAPI-74
3 · Its place in the literature

Who cites it

154 citing papers in PubMed, 5 syntheses or guidelines pooled it, 290 citations in OpenAlex.

  1. Head-to-head comparative study of [Frontiers in oncology · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Diagnostic performance of [Frontiers in medicine · 2025
    Pooled it
  5. Pooled it
  6. Assessment of liver fibrosis and tumor burden in hepatocellular carcinoma using [European journal of nuclear medicine and molecular imaging · 2026
    Trial
  7. Assessment of the diagnostic efficacy and clinical significance of [European journal of nuclear medicine and molecular imaging · 2026
    Trial
  8. Trial
  9. Clinical Evaluation of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  10. Easy and versatile preparation ofEJNMMI radiopharmacy and chemistry · 2026
    Article
  11. Automated and manual synthesis of [EJNMMI radiopharmacy and chemistry · 2026
    Article
  12. Review
  13. Review
  14. Article
  15. European journal of nuclear medicine and molecular imaging · 2026
    Article
  16. Comparison between [EJNMMI research · 2026
    Article
  17. Article
  18. Article
  19. Combined antitumor activity of [EJNMMI research · 2026
    Article
  20. Article

94 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Frederik L GieselDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Sebastian AdebergHeidelberg Institute of Radiation Oncology, Heidelberg, Germany.
Mustafa SyedHeidelberg Institute of Radiation Oncology, Heidelberg, Germany.
Thomas LindnerDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Luis David Jiménez-FrancoABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH, Dresden, Germany.
Eleni MavriopoulouDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Fabian StaudingerDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Eric Tonndorf-MartiniHeidelberg Institute of Radiation Oncology, Heidelberg, Germany.
Sebastian RegneryHeidelberg Institute of Radiation Oncology, Heidelberg, Germany.
Stefan RiekenHeidelberg Institute of Radiation Oncology, Heidelberg, Germany.
Rami El ShafieHeidelberg Institute of Radiation Oncology, Heidelberg, Germany.
Manuel RöhrichDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Paul FlechsigDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Andreas KlugeABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH, Dresden, Germany.
Annette AltmannDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Jürgen DebusHeidelberg Institute of Radiation Oncology, Heidelberg, Germany.
Uwe HaberkornDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany uwe.haberkorn@med.uni-heidelberg.de.
Clemens KratochwilDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
University Hospital Heidelberg · DEHeidelberg University · DEABX-CRO Advanced Pharmaceutical Services (Germany) · DEHeidelberger Institut für Radioonkologie · DEUniversitätsmedizin Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Positron Emission Tomography Computed TomographyAgedAluminum CompoundsBiological TransportFemaleFluoridesGallium RadioisotopesHumansIsotope LabelingLung NeoplasmsMaleMiddle AgedRadiometryTemperatureTissue DistributionAluminum Compoundsaluminum fluorideFluoridesGallium-68Gallium Radioisotopescancer-associated fibroblastscold kitFAPI PET/CTlung cancerradiation dosimetry

Identifiers

PMID32591493
PMCPMC8679591
OpenAlexW3037670955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.